Benzinga · Nov 10, 2026
Why Is Humana Stock Trading Higher Tuesday?
Humana (HUM) stock jumped over 3% following a new cancer care initiative and a raised 2026 earnings outlook. Read the latest updates.
EV
NYSE · EVH
Evolent Health, Inc.
Healthcare · Medical - Healthcare Information Services
$4.77
Down-$0.07 (-1.47%)
Updated Nov 13, 2026, 3:20 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 453.39M
- P/E ratio
- -3.35
- Dividend yield
- 0.00%
- 52-week range
- $2.10 – $6.26
- Volume
- 1.39M
- Avg. volume
- 3.7M
Price performance · EVH
EVH price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 12, 2026
EVH closed at $4.77 after 21 trading sessions, down 2.05% for the selected period.
- Last close
- $4.77
- Period change
- -2.05%
- Period low
- $4.25
- Period high
- $4.99
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | $4.96 | $4.99 | $4.65 | $4.77 | 1.39M |
| Nov 11, 2026 | $4.78 | $5.005 | $4.77 | $4.99 | 2.2M |
| Nov 10, 2026 | $4.64 | $4.905 | $4.56 | $4.80 | 1.75M |
| Nov 9, 2026 | $4.55 | $4.84 | $4.38 | $4.71 | 2.15M |
| Nov 6, 2026 | $4.51 | $4.82 | $4.39 | $4.58 | 1.74M |
| Nov 5, 2026 | $4.25 | $4.96 | $4.25 | $4.54 | 3.5M |
| Nov 4, 2026 | $4.44 | $4.975 | $4.42 | $4.80 | 2.6M |
| Nov 3, 2026 | $4.45 | $4.45 | $4.27 | $4.30 | 1.26M |
| Nov 2, 2026 | $4.33 | $4.55 | $4.18 | $4.45 | 1.43M |
| Oct 30, 2026 | $4.26 | $4.31 | $4.085 | $4.30 | 1.15M |
| Oct 29, 2026 | $4.39 | $4.42 | $4.21 | $4.25 | 1.3M |
| Oct 28, 2026 | $4.28 | $4.48 | $4.265 | $4.33 | 2.15M |
| Oct 27, 2026 | $4.60 | $4.60 | $4.365 | $4.42 | 1.48M |
| Oct 26, 2026 | $4.79 | $4.85 | $4.36 | $4.53 | 1.73M |
| Oct 23, 2026 | $4.86 | $4.9499 | $4.755 | $4.80 | 1.23M |
| Oct 22, 2026 | $4.84 | $4.935 | $4.79 | $4.89 | 1.31M |
| Oct 21, 2026 | $4.90 | $4.94 | $4.77 | $4.83 | 1.47M |
| Oct 20, 2026 | $4.52 | $4.895 | $4.51 | $4.87 | 1.18M |
| Oct 19, 2026 | $4.52 | $4.625 | $4.385 | $4.48 | 1.64M |
| Oct 16, 2026 | $4.89 | $4.95 | $4.55 | $4.57 | 2.08M |
| Oct 15, 2026 | $4.75 | $5.115 | $4.75 | $4.87 | 3.84M |
Latest EVH news
The latest Smart Investors Daily articles mentioning EVH.
Stock researchCompany · Overview
Company
Market Activity
Research & News
EVH research
Overview
Company profile and research snapshot.
Company profile
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 6, 2026 | Oppenheimer | Outperform | — |
| Nov 5, 2026 | Needham | Buy | — |
| Aug 18, 2026 | JP Morgan | Overweight | — |
| Aug 17, 2026 | TD Cowen | Buy | — |
| Aug 12, 2026 | Truist Securities | Hold | — |
News briefing
No generated briefing is available yet.
Benzinga · Nov 10, 2026
Humana Partners With Evolent Health, American Oncology Network To Introduce New Cancel Care Model In 8 U.S. States
Humana Inc., in collaboration with Evolent Health, Inc. and American Oncology Network (AON), today announced the launch of a new cancer care model designed to improve the quality, timeliness and affordability of cancer
Yahoo · Nov 9, 2026
EVH Q3 2026 deep dive: ongoing AI investment and customer expansion shape outlook
Healthcare solutions company Evolent Health (NYSE:EVH) met Wall Street’s revenue expectations in Q3 2026, with sales up 51.3% year on year to $725.4 million. The company’s full-year revenue guidance of $2.65 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $0.06 per share was in line with analysts’ consensus estimates.
SeekingAlpha · Nov 7, 2026
Evolent Health, Inc. (EVH) Q3 2026 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q3 2026 Earnings Call November 5, 2026 8:30 AM ESTCompany ParticipantsSeth Blackley - Co-Founder, CEO & DirectorMario Ramos -...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
